Alexion Pharmaceuticals (ALXN) Tops Q2 Views; Guides Higher
More News related to ALXN
- Alexion to Present at the 20th Annual Piper Jaffray Health Care Conference
- Alexion Pharmaceuticals' (ALXN) Keiser to Retire
- David W. Keiser to Retire as President of Alexion
- Researchers to Present Additional Data on Soliris(R) (eculizumab) for the Treatment of PNH at the ASH Annual Meeting
- Alexion to Present at Investor Conferences
More News related to Earnings
- Unusual 11 Mid-Day Movers 12/03: OGXI, PPO, BZH, GW Higher; IFX, HSNI, FCX, PALM Lower
- Notable Analyst Rating Changes 12/03: LMT, DRI, CTAS Upgraded; ALO, SYK, FSLR Downgraded
- Morning Movers 12/03: Constellation Energy (CEG) Jumps On Alternative Bid From EDF, Schlumberger (SLB) Down On Warning
- Notable Mergers and Acquisitions of the Day 12/03: CEG, MTZ, RIMM
- After-Hours Movers 12/02: Omnivision (OVTI) Lower on Guidance, Marvell Tech (MRVL) Up on Results
Alexion Pharmaceuticals (Nasdaq: ALXN) reports Q2 earnings of $0.06 per share, above the consensus of a $0.14 loss. Revenues came in at $59.6 million versus the consensus of $54 million.
Sees $235-$245 million versus prior guidance of $215-$225 million and the consensus of $228.4 million.
Related Categories
EarningsGuidance
Hot List
Stocks Mentioned
-1.01Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
